# Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

> **NCT03678025** · PHASE3 · RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 1273 (estimated)

## Conditions studied

- Castration Levels of Testosterone
- Metastatic Prostatic Adenocarcinoma
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Abiraterone
- **DRUG:** Bicalutamide
- **DRUG:** Degarelix
- **DRUG:** Docetaxel
- **DRUG:** Flutamide
- **DRUG:** Goserelin Acetate
- **DRUG:** Histrelin Acetate
- **DRUG:** Leuprolide Acetate
- **DRUG:** Nilutamide
- **PROCEDURE:** Orchiectomy
- **DRUG:** Prednisone
- **OTHER:** Quality-of-Life Assessment
- **RADIATION:** Radiation Therapy
- **PROCEDURE:** Radical Prostatectomy
- **DRUG:** Triptorelin

## Key facts

- **NCT ID:** NCT03678025
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-09-24
- **Primary completion:** 2028-04-01
- **Final completion:** 2031-10-01
- **Target enrollment:** 1273 (ESTIMATED)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03678025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03678025, "Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03678025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*